Advanced Filters
noise

A, Almada N Clinical Trials

A listing of A, Almada N clinical trials actively recruiting patients volunteers.

Found 10,489 clinical trials
L Laurent SATTLER, PharmD

Long-term Anticoagulation in a Patient With Severe Hemophilia A

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between …

18 years of age All Phase N/A

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight …

18 - 45 years of age Male Phase 1
S Shuo Chen, MD

A Study of FVIII Gene Therapy for Hemophilia A

This is a single-arm, open-label, clinical study to evaluate the safety, tolerability of BBM 002 injection in Hemophilia A subjects with residual factor VIII (FVIII) levels ≤2 International unit per deciliter (IU/dl) . BBM 002 injection is an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an …

18 years of age Male Phase N/A
S Shuo Chen, MD

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT003 in hemophilia A patients. NGGT003 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human FVIII gene B domain deletion mutant …

18 years of age Male Phase N/A

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Sobi.BIVV001-003 is an open-label, 2-period, fixed sequence study for intra-participant comparison of the PK profiles of efanesoctocog alfa and the extended half-life rFVIII products damactocog alfa pegol or turoctocog alfa pegol after a single i.v. injection in previously treated males, 18-65 years of age, with severe haemophilia A. Participants who …

18 - 65 years of age Male Phase 1
S Shuo Chen, MD

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

This study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor

12 - 70 years of age All Phase 3

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \<12 years) who have severe hemophilia A or B, with or without inhibitory antibodies to FVIII or FIX. Number of participants: Approximately …

1 - 11 years of age Male Phase 3
X Xiangyang Wang, MD

Effect of Vitamin A Supplementation on Idiopathic Scoliosis

This study aims to investigate whether vitamin A supplementation can influence spinal curve magnitude in idiopathic scoliosis children and potentially prevent its de novo development.

6 - 15 years of age All Phase N/A
Y YU Chen, MD

The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure

This is a multicenter, randomized, controlled, open-label phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure(ACLF). Phase 1 is a multicenter, open label study to …

18 - 65 years of age All Phase 1

CandyCollect Strep Throat Testing

This study will enroll children ages 5-17 who test positive for Group A Streptococcus (GAS) at a single clinic visit lasting approximately 30-60 minutes. The primary aim of this study is to assess the accuracy and feasibility of the CandyCollect platform to capture and detect GAS. The investigators hypothesize that …

5 - 17 years of age All Phase N/A

Simplify language using AI